HomepageMedicinePar Pharmaceutical Issues Recall of Single Lot of Treprostinil Medicine Par Pharmaceutical Issues Recall of Single Lot of Treprostinil admin Posted on March 14, 2024 The voluntary recall was ordered due to potential silicon particulate exposure. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostWho Moved My Cheese? Ways To Help A Cat Through Change Next PostWill She Make the Next Birkin Bag? You Might Also Like Medicine FDA Approves Luye Pharma Group’s Erzofri for Adults with Schizophrenia, Schizoaffective Disorder admin July 31, 2024 Medicine Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications admin November 27, 2024 Medicine A Decade of Data Under the Belt admin April 6, 2024 Medicine Pharma Pulse 11/4/24: Community Pharmacies in Crisis, Insights Into ADHD Diagnoses in Adult Women & more admin November 5, 2024
Medicine FDA Approves Luye Pharma Group’s Erzofri for Adults with Schizophrenia, Schizoaffective Disorder admin July 31, 2024
Medicine Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications admin November 27, 2024
Medicine Pharma Pulse 11/4/24: Community Pharmacies in Crisis, Insights Into ADHD Diagnoses in Adult Women & more admin November 5, 2024